Bio News
U.S. Rep. Nathaniel Moran of Texas said China is ahead of the United States in the early stages of the new drug supply chain. He noted that Chinese assets are expected to account for more than two-thirds of the value of global technology-transfer deals this year. Moran expressed concern that U.S. pharmaceutical research and development and its knowledge base are rapidly shifting to China.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
